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Dengue  is a rapidly  growing  public  health  threat  with  approximately  2.5 billion  people  estimated  to  be
at  risk.  Several  vaccine  candidates  are  at various  stages  of pre-clinical  and  clinical  development.  Thus
far,  live  dengue  vaccine  candidates  have been  administered  to several  thousands  of  volunteers  and  were
well-tolerated,  with  minimal  short-term  safety  effects  reported  in Phase  I  and  Phase  II  clinical  trials.
Based  on the  natural  history  of  dengue,  a theoretical  possibility  of  an  increased  risk  of  severe dengue as
a  consequence  of vaccination  has  been  hypothesized  but  not  yet  observed.  In October  2011,  the  World
Health  Organization  (WHO)  convened  a consultation  of  experts  in  dengue,  vaccine  regulation  and  vaccineaccine safety
ost-licensure monitoring
safety  to review  the  current  scientiﬁc  evidence  regarding  safety  concerns  associated  with  live  attenuated
dengue  vaccines  and,  in particular,  to  consider  methodological  approaches  for  their  long-term  evaluation.
In  this  paper  we  summarize  the  scientiﬁc  background  and  methodological  considerations  relevant  to  the
safety  assessment  of  these  vaccines.  Careful  planning  and  a coordinated  approach  to  safety  assessment
are  recommended  to  ensure  adequate  long-term  evaluation  of dengue  vaccines  that will  support  their
introduction  and  continued  use.
aniza© 2013 World Health Org
. Introduction
Dengue is the most rapidly spreading mosquito-borne viral dis-
ase globally, with more than a 30-fold increase in the annual
umber of cases reported to WHO  in the last 50 years and increas-
ng numbers of countries affected, including both urban and rural
ettings [1,2]. Dengue virus, belonging to the Flavivirus genus, has
our antigenically distinct serotypes (DENV1–4), each of which is
Abbreviations: ADE, antibody-dependent enhancement; DENV, dengue virus;
ATDV,  live attenuated tetravalent dengue vaccine; PBMC, peripheral blood
ononuclear  cells; SAE, serious adverse event; WHO, World Health Organization.
 Disclaimer: This report contains the collective views of an international group
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o  not necessarily represent the decisions, policy or views of the World Health
rganization.
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Open access ution. Published by Elsevier Ltd.
capable of causing disease in humans when transmitted through
the bite of Aedes mosquitoes. The clinical disease usually mani-
fests as an acute febrile illness, or dengue fever, but occasionally
develops into severe dengue. WHO  estimates that approximately
2.5 billion people are at risk from dengue, and 50–100 million
dengue infections occur annually of which about 500,000 are cases
of severe dengue requiring hospitalization [3]. There is no licensed
dengue vaccine and prevention is exclusively through vector con-
trol. Successful introduction of safe and effective dengue vaccines
will be a critical step in preventing dengue infection and disease.
Several vaccine candidates are in pre-clinical development, and
some are undergoing clinical trials [4–6]. The most advanced live
attenuated tetravalent dengue vaccine (LATDV) candidate, which is
currently undergoing Phase III clinical trials, is a chimeric vaccine
combining the preM and E genes of dengue with the yellow fever
17D-backbone [7].
Open access under CC BY-NC-ND license.While  dengue pathogenesis is recognized to be complex, sev-
eral viral, clinical and epidemiological studies have advanced the
understanding of aspects critical to vaccination as summarized in
previous reviews [8–11]. Infection with a speciﬁc DENV serotype
  nder CC BY-NC-ND license.
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roduces immunity to that serotype that is thought to be life-long
ut only short-term protection, of 3–6 months, against other
erotypes. The most important risk factor for severe disease is
revious infection, most commonly after a second (and rarely
hird) infection with a different DENV serotype than the previous
nfection(s) [12,13]. Severe disease is 15–80 times more common
n secondary compared to primary infections [14]. Observations in
engue-infected infants born to dengue-immune mothers suggest
n increased risk for severe disease associated with decline of
aternally derived neutralizing antibodies to sub-neutralizing
oncentrations [15]. These observations and other epidemiological
vidence underlie the concept of antibody-dependent enhance-
ent (ADE) of disease as a primary mechanism triggering the
evelopment of severe disease in secondary infections [9,15,16].
Different  mechanisms for the immune enhancement of disease
re hypothesized to contribute to severe dengue. “Extrinsic ADE” is
elieved to result from non-neutralizing antibodies or neutralizing
ntibodies at concentrations below their neutralization capacity
hat enhance viral entry into host cells by forming complexes
ith the virus and binding to Fc-receptors on the host cells [16].
n addition, attachment and entry of virus-antibody complexes
nto Fc receptor-bearing cells has been proposed to modify innate
nd adaptive intracellular antiviral mechanisms and enhance
eplication (“intrinsic ADE”) [15]. Other mechanisms of immune
nhancement involving cellular immune responses have been sug-
ested [17,18]. The risk of severe disease is thought to depend on
he balance and nature of the T-cell response which may  favour
nti-viral activity or the secretion of pro-inﬂammatory cytokines
hat facilitate plasma leakage. These hypothesized mechanisms
f immune enhancement are not unrelated because antibody-
ediated increase of viral replication would result in a greater
umber of dengue-infected cells that would elicit a greater T-
ell response, and presumably a stronger but aberrant immune
esponse leading to more severe disease. In addition, large amounts
f NS1 generated by enhanced DENV replication could bind to
erum complement with generation of anaphylatoxin C5a and
ncreased vascular leakage [19].
A key challenge in the development of dengue vaccines is the
imited understanding of the complexity of dengue immunology
nd pathogenesis, including a potential risk of sensitization to
evere disease (i.e., immune enhancement) following vaccination.
ngoing clinical trials for candidate LATDVs, taking into account
he relevant WHO  guidance for long term assessment of dengue
accines [4,20], will assess the potential risk of immune enhance-
ent for periods of up to 5 years, however more robust information
ill be needed from post-licensure studies.
Post-licensure vaccine introduction strategies will need to con-
ider assessments of the long-term safety and effectiveness of the
accine in addition to other common parameters for vaccination
uch as the target population (age groups and regions), vaccine
elivery (e.g., mass vaccination campaigns or routine immunization
ith or without catch-up campaigns), scheduling, use in special
opulations not included in clinical trials, coverage targets, and
o-administration with other vaccines.
With the ﬁrst LATDV candidate now in Phase III trials there
s a need for further, more detailed, guidance on strategies for
ong-term monitoring of vaccine safety. WHO  convened an expert
onsultation in October 2011 to initiate review of the current data
egarding potential safety risks associated with LATDVs. Experts
eviewed aspects of the post-licensure evaluation of LATDVs,
ncluding potential diagnostic approaches for dengue and study
esign issues. This paper summarizes the key deliberations and
onclusions of the consultation. Candidate dengue vaccines based
n other technologies in earlier stages of clinical development or
n preclinical studies [6] were not discussed but many of the con-
iderations discussed here may  also apply.ne 31 (2013) 2603– 2609
2.  Dengue vaccine-speciﬁc safety considerations
Current WHO  guidelines recommend that safety assessment of
dengue vaccines should include follow-up of dengue-vaccinated
and control subjects for at least 3–5 years after completion of pri-
mary vaccination in Phase II and Phase III trials [4,20]. Evidence
from settings with different mosquito transmission intensities
will be desirable as boosting from natural infection and differ-
ent circulating serotypes and genotypes may  impact on vaccine
safety.
Present LATDV candidates have been shown to induce very
low levels of viraemia and have been well-tolerated in healthy
ﬂavivirus-naïve adults [21–23]. In children, some studies showed
more local and systemic reactions after the ﬁrst dose than after
subsequent doses and fever was more frequent than in adults
[23–26]. However, no dengue-like illness caused by the vaccine
has been reported in clinical trials of current candidate vaccines.
Nonetheless, the risk of dengue-like illness following vaccination
remains a potential safety concern for LATDVs, and the safety pro-
ﬁle will need to be corroborated in special populations, such as
HIV-infected and other immunocompromised individuals. An ear-
lier clinical trial reported a breakthrough case of wild-type DENV
infection with uncomplicated febrile illness in an adolescent vac-
cinee with onset 4 days after the second vaccination dose [24].
However, to date, there have been no indications of an increased
risk of severe dengue disease following vaccination, based on sev-
eral thousand doses of varying LATDV candidates administered in
clinical trials [7,11,27].
Vaccine-associated dengue-like disease can potentially occur
as an early or later onset event after vaccination. Early post-
vaccination dengue may theoretically result from vaccine viraemia
but is unlikely due to the low level of replication of the attenu-
ated viruses. Of more potential concern is enhancement due to
infection with wild-type DENV before the full immune response
to vaccination has developed or as a later post-vaccination adverse
event. Evidence for such risks has not been identiﬁed to date in
pre-licensure trials of current candidate vaccines.
Later onset post-vaccination dengue might result from immune
enhancement following infection by a wild-type DENV in indi-
viduals with insufﬁcient protective immunity generated by the
primary immunization series or waning immunity over time result-
ing in susceptibility to one or more wild DENV serotypes. Such late
effects may  be related to the interval between completed vacci-
nation and subsequent wild-type DENV exposure, the viral load
from wild-type DENV infection(s) and the level of immunity at the
time of that exposure and, depending on the local epidemiology
of dengue infections, could manifest many years post-vaccination
[13].
Depending on the speciﬁc vaccine construct, other safety con-
siderations may  apply, such as viscerotropic disease for yellow
fever vaccine chimeric constructs [28].
Only a small percentage of patients with secondary natural
infections, estimated as 2–4% in one review [29], develop severe
dengue. Moreover, severe disease can occur after primary infec-
tion, in the absence of maternally derived antibody, suggesting
a complex, multifactorial pathogenesis [30]. In addition to the
immune mechanisms for severe disease discussed above, a num-
ber of risk factors have been proposed based on the natural history
of dengue, as outlined below. The role, if any, of such factors in
severe dengue following vaccination are unknown and may  jus-
tify inclusion in special safety studies. Varying levels of evidence
have been observed in different settings, suggesting that speciﬁc
attention should be given to collecting safety data from a variety of
transmission settings and target populations.
Age: A higher relative incidence of severe dengue has been
reported in infants and younger children and is thought to
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e linked to greater permeability of the vascular endothelium
31–33].
Gender: Higher degrees of severity and mortality are reported in
irls, however it is possible that this is due to differences in health-
eeking behaviour [9].
Genetic factors: Studies of speciﬁc viral and host genotypes sug-
est different levels of virulence in DENV strains and that host
enotype may  increase susceptibility to severe disease [9,34].
Sequence  of the infecting serotypes: The highest risk of severe
engue following secondary infection has been reported with
ENV2 [35,36]. However, reported risks of severe disease vary with
 different order of serotypes in the primary and secondary infec-
ions, suggesting other important risk factors besides the sequence
f infecting serotypes.
Interval  between infections: Data from Cuba suggest that longer
ntervals between infections result in more severe disease. Fol-
owing a 1977 DENV1 epidemic, severe dengue and death in
ubsequent DENV2 epidemics occurred in 5% and 0.1% of infected
ersons respectively in 1981, and 42% and 2.3% respectively in 1997
13]. Further evidence from a cohort study in Thailand showed the
verage time interval between two infections, among subjects with
engue seronegative (hemagglutination inhibition) status at enrol-
ent, was 1.4 years for asymptomatic patients, 1.9 years for dengue
ever and 2.6 years for dengue haemorrhagic fever [37].
Other virological factors: The potential for selective immune
ressure resulting in escape of variant DENV strains is an impor-
ant consideration. Epidemiological characteristics of dengue do
ot suggest immune escape by antigenically variant viruses within
 serotype in natural human infections and the available experi-
ental data also suggest that all genotypes of a given serotype are
eutralized by polyclonal antibodies [38,39]. Nonetheless, ongo-
ng virus surveillance is crucial [4] and the possibility of increased
isk of disease associated with mutant DENV strains need further
tudy, including the severity and characteristics of dengue disease
hat may  result. Because of this, DENVs that cause disease post-
accination should be systematically isolated and sequenced.
Genetic,  antigenic and phenotypic diversity exist within each
ENV serotype [40]. The level of efﬁcacy that a particular LATDV
nduces may  vary by genotypes and serotypes, and may  therefore
ffect its long-term safety with respect to the risk of enhanced dis-
ase. Hence, long-term studies should, whenever possible, examine
irculating genotypes, duration of protection and herd effects.
.  Methodological considerations
As  with other vaccines, key outcomes of interest in the post-
icensure evaluation of safety and effectiveness for LATDVs will
nclude (a) serious adverse events (SAEs) too rare (<1 in 1000) for
etection with conﬁdence to have been detected in pre-licensure
rials; (b) SAEs with a long latency not detected in pre-licensure
rials; (c) adverse events in groups who may  have been excluded
rom pre-licensure trials, such as immune-compromised persons;
d) the level of protection against dengue and severe dengue under
eld conditions; (e) potential waning of protection and the need
or boosters; and (f) evidence of herd protection.
Considerations of safety and efﬁcacy are inseparably related for
engue vaccines as severe dengue disease is a theoretical adverse
eaction as well as an endpoint against which the vaccines are
esigned to protect. Based on the deliberations of the consultation,
 framework is proposed for the long-term assessment of LATDVs
Table 1). The issues for consideration in the framework are grouped
ccording to pre-licensure and post-licensure vaccine use. Potential
afety risks are discussed as early and later post-vaccination events
s described above. The phase of vaccine introduction and use
pre-licensure or post-licensure) and respective post-vaccinationne 31 (2013) 2603– 2609 2605
windows for early or later adverse events pose different issues for
study design. We  give special attention to the long-term assess-
ment of immune enhancement of disease.
3.1. General methodological issues
3.1.1. Dengue transmission
The  design of long-term studies should take into account the
need to assess vaccine performance in a variety of settings with
different transmission intensities and the potential impact of vac-
cine coverage levels on mosquito transmission and herd immunity.
Both baseline and longitudinal data on circulating DENV serotypes
will be of critical importance for the interpretation of these studies.
3.1.2. Ethical issues
An  ethical and logistic issue concerns the inclusion of
unvaccinated comparison groups (other than those who  refuse
vaccination) in studies after a dengue vaccine has been proven
efﬁcacious and is licensed. Experts at the consultation took into
account that, based on current practices for scaling up new vaccines
after ﬁrst introduction, the ﬁrst LATDVs are likely to be unavailable
for large numbers of individuals for some period after licensure
even in endemic countries. Thus, in some settings, unvaccinated
“controls” may  be available for comparative studies until there is
widespread public health use of the vaccine. There might also be
an opportunity for a coordinated staggered vaccine introduction.
3.1.3.  Ascertaining vaccination status and infection exposure
Accurate ascertainment of vaccination status by dosage and
timing (including any vaccination of subjects in control groups
during long observation periods) and disease endpoints (particu-
larly severe dengue-like illness) may  be challenging for long-term
studies. Access to accurate vaccination data through vaccine reg-
istries is needed and such registries should be established wherever
possible, at least for early introducer countries. Documentation
and assessment of post-vaccination asymptomatic exposure to
dengue virus is likely to be difﬁcult in the general population.
However, for special studies, regular serological testing in a sub-
group of vaccinees would be desirable to assess any boosting
effects of repeated exposures and for monitoring of non-severe
dengue. Dengue surveillance systems and laboratory diagnos-
tic capacities are likely to be of variable quality in countries
where the vaccine is introduced and efforts should be made to
enhance surveillance. There are strong arguments for establishing
a number of sentinel sites, with good surveillance and diagnostic
capacities, to support long-term (>5 years) safety studies. Priority
should be given to establishing sentinel sites in early introducer
countries.
3.1.4. Immune monitoring
Where  possible, long-term studies should be designed to obtain
samples of sera and peripheral blood mononuclear cells (PBMCs)
from participants pre-vaccination, at the end of vaccination and
periodically thereafter [20]. This will enable study of asymptomatic
infections, correlates of protection, the need for booster doses
prompted by declining DENV antibody titres, and of biomarkers for
the risk of severe dengue. Such repeated blood sampling is likely
to be more feasible in the follow-up of clinical trial subjects than
in post-licensure studies. As previously recommended, collected
samples should be stored for retrospective analysis of dengue cases
[20].3.2. Issues speciﬁc to long-term follow-up of clinical trial subjects
To  supplement the WHO  guidance on safety monitoring of LAT-
DVs during clinical trials [4,20], the experts at the consultation
2606 A.D. Bentsi-Enchill et al. / Vaccine 31 (2013) 2603– 2609
Table  1
Framework for the assessment of live attenuated tetravalent dengue vaccines, including considerations for special long-term studies.
Pre-licensure phasesa of dengue vaccine use Post-licensure phasea of dengue
vaccine use
Key safety questions (especially those
that are more speciﬁc to dengue
vaccines, including thepotential risk of
severe dengue post-vaccination)
Early  post-vaccination eventsb
• Risk of post-vaccination dengue-like disease caused by vaccine viraemia
• Risk of immune-enhanced dengue causedby wild-type dengue virus (DENV) infection in
persons  with incomplete protectionat inter-dose intervals or before development of full
immune response (after the last vaccine dose)
Later post-vaccination eventsb
• Risk of immune-enhanced dengue from wild-type DENV infection post-vaccination due to
insufﬁcient  vaccine-induced serotypicimmune response or waning immunity, or more virulent
serotype infection that mimics severe dengue without contribution of immune enhancement
Additional safety issues
•  Risk of rare serious adverse events (SAEs), of early or late onset, e.g., viscerotropic or
neurotropic disease related to the dengue chimeric vaccine employing a yellow fever vaccine
backbone
•  Risk of other unexpected adverse
events
Study population(s) • Clinical trial subjects, including
ﬂavivirus-naive and ﬂavivirus-immune
individuals
The  priority study populations may  be
determined according to the stage and
strategy of vaccine introduction
• Special populations and situations for assessment of
speciﬁed  safety questions, usually in Phase III trials
(e.g.,  immunocompromised persons, co-morbidities,
co-administration with other vaccines)
• Before general public health use: If
considered necessary beyond studies
in the pre-licensure period, Phase IV
studies may  be carried out in trial
settings (including special populations
and situations e.g.,
immunocompromised persons,
co-administration with other vaccines)
• At introduction into public health
use: Phase IV studies in early
introducer countries
•  During routine or general public
health use: Phase IV studies in early
introducer or selected countries.
(Special studies for late events only if
neededc)
Possible study designs Individually randomized controlled trials (±
nested case–control studies)
•  Before general public health use:
Randomized controlled trials (± nested
case–control studies)
Key  issues in study design: • At introduction into public health
use: Phased introduction, e.g., stepped
wedge design, gives opportunity to
assess (a) risk proﬁle by time since
vaccination and (b)
effectiveness/public health impact
• Study designs should enable assessment of
protection and risk proﬁle for all 4 serotypes –
not  necessarily in the same study population
• During routine or general public
health use: Case–control studies or
cohort studies. Case-only studies may
be appropriate for early adverse events
• For long-term follow up, there are ethical
constraints regarding how long an
unvaccinated control group can be maintained
once there is substantial evidence of efﬁcacy
Additional considerations:
•  Consider possibility to bleed all or most
participants at the end of primary vaccination,
and periodically thereafter, to study correlates
of protection and biomarkers of risk
• Surveillance for safety signals may
be done through routine monitoring in
the post-licensure phase
• Studies should assess if and when booster
doses should be given
•  Special studies and/or enhanced
detection and virological work up may
be requiredfor some speciﬁc SAEs
and/or signals
a Long-term follow-up of vaccinees in Phase II and Phase III trials may  extend to the post-licensure period for a given vaccine.
b “Early events” are deﬁned here as adverse events occurring from ﬁrst vaccination and up to approximately 21 days after the last dose in the primary series. “Later events”
a nts an
trodu
p
d
L
r
a
s
cre deﬁned as adverse events occurring at any time beyond the period for early eve
c May  be considered if long-term studies are not planned with early vaccine in
rovide reliable data.
iscussed additional considerations for the assessment of safety.
ong-term follow-up of clinical trial subjects beyond the cur-
ent guideline of 3–5 years post-vaccination, should continue for
s long as possible to better describe the safety proﬁle. This
hould be done whether or not an unvaccinated control group
an be maintained. Decisions regarding an unvaccinated arm ind may  extend to many years post-vaccination.
cer countries “at introduction into public health use” or if they are inadequate to
comparative  studies post-licensure will require inputs from spon-
sors, regulatory authorities, ethics committees and data safety
monitoring boards. There are precedents for extended follow-
up of vaccinated and unvaccinated participants in other studies,
beyond the time when short-term efﬁcacy has been established
[41–43].
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The risks of early and later adverse events will need to be eval-
ated in clinical trial populations, including subjects who were
avivirus-naïve and ﬂavivirus-immune pre-vaccination. Safety and
fﬁcacy may  also need to be established in speciﬁc population
roups potentially at higher risk but excluded from earlier trials
e.g., HIV-infected persons or pregnant women). Some potential
isk groups may  be too small to justify speciﬁc trials (such as per-
ons with certain immunodeﬁciency syndromes or other clinically
igniﬁcant co-morbidities such as diabetes and sickle cell anaemia,
r those receiving immune-modulating drugs), but in these groups
AEs should be monitored through speciﬁc assessment protocols.
.3.  Possible study designs for long-term safety assessment
ost-licensure
The selection of appropriate study designs will depend on the
tage and strategy of vaccine introduction in a speciﬁc setting.
.3.1.  Before general public health use
There may  be opportunities for setting up studies before any
engue vaccines are marketed for widespread use in a country,
r in the period between the completion of Phase III studies and
accine licensure. In this period, it may  be possible to use ran-
omized controlled studies to assess both effectiveness (including
erd protection with cluster randomized designs) and safety. Eth-
cal limitations on maintaining unvaccinated comparison groups
ay be less challenging under these conditions but are still likely
o limit the duration of follow-up [43,44].
.3.2. At introduction into public health use
Where phased introduction of an LATDV for routine use is being
onsidered, a stepped-wedge design may  be possible, in which
opulations in different geographical areas are vaccinated at differ-
nt times, allowing those who are unvaccinated at any given stage
o serve as controls until they are vaccinated [45]. The stepped-
edge design is generally more acceptable than a randomized
ontrolled trial or a cluster-randomized trial for post-licensure
tudies. Its usefulness in the context of LATDVs is likely to be limited
o the assessment of early post-vaccination events, as it may  not be
cceptable to maintain unvaccinated comparison groups for long
eriods.
.3.3. During routine or general public health use
Methodologically and logistically, case–control studies are the
asiest and most feasible option, although ensuring accurate ret-
ospective ascertainment of vaccination status may  be challenging
nd the statistical power of such studies is compromised in situ-
tions of high vaccine coverage. Prospective cohort studies have
he advantage that vaccine status can be accurately recorded but
n some situations there may  be an ethical obligation to offer vac-
ine to unvaccinated controls. Retrospective cohort designs may  be
ossible in settings where accurate records of vaccination and dis-
ase outcomes are available, such as through linked computerized
atabases.
Difﬁculties in the interpretation of both case–control and cohort
tudies arise from the non-random allocation of vaccination and
he challenges of adjusting adequately for confounding factors (e.g.,
hose at the highest risk of disease might be most (or least) likely to
resent for vaccination). For some vaccines, case-only studies have
roved useful for assessment of potential adverse effects occurring
hortly after vaccination [46] and this design may  also be consid-
red for early events following dengue vaccination. As with the
ther designs, case-only studies require reliable ascertainment of
accination status as well as disease outcomes. Their design relies
n a hypothesized window of increased risk following vaccina-
ion and thus for LATDVs would be less applicable for assessingne 31 (2013) 2603– 2609 2607
later  post-vaccination adverse events for which the period of risk
is currently undetermined.
In  addition to special studies, the introduction of LATDVs should
be used as an opportunity to strengthen routine systems for post-
marketing surveillance of adverse events following immunization.
This may  be foreseen through global or regional activities such as
the Global Vaccine Safety Initiative [47]. Some SAEs, such as sus-
pected cases of viscerotropic and neurotropic disease following the
yellow fever chimeric vaccine, may  require enhanced surveillance
and virological work up [28].
4. Other considerations
4.1.  Ascertainment of severe dengue
There are potential challenges with regard to both the deﬁnition
of dengue disease and classiﬁcation of case severity, including the
availability of diagnostic tools for severity ascertainment (e.g., dif-
ﬁculties with plasma leakage assessment in low-resource settings).
Furthermore, there are currently no diagnostic assays to distin-
guish severe dengue cases due to potential vaccine-associated
immune enhancement from those cases due to vaccine failures.
Therefore, assessment of risk-beneﬁt will depend upon epidemi-
ological approaches. Cases of severe dengue are more likely to
be captured by dengue surveillance than by weak adverse event
surveillance systems. Experts at the consultation discussed the ade-
quacy of the current WHO  dengue case classiﬁcation [1] to monitor
post-vaccination dengue illness and concluded that further work
is warranted to ensure complete, accurate and harmonized classi-
ﬁcation of cases in the context of monitoring long-term safety and
effectiveness of dengue vaccines.
4.2. Diagnostics
Various diagnostic tests for dengue infection are available, some
of which are able to distinguish different DENV serotypes [48]. Due
to molecular differences between wild-type dengue viruses and
vaccine viruses, virus sequencing and other assays will be essen-
tial to assess the causality of dengue-like illness occurring shortly
after vaccination. For example, chimeric yellow fever dengue vac-
cine viruses can be distinguished from naturally occurring dengue
viruses by assays detecting nucleic acid, antigens and antibodies
speciﬁc to the yellow fever non-structural genes.
Collection and long-term storage of relevant samples from vac-
cinees (e.g., serum, PBMCs) should be encouraged, as this could
greatly facilitate efforts to determine correlates of protection, pos-
sible booster needs and potential biomarkers, which may  be used
in the future to identify vaccinees at risk of dengue disease.
4.3.  Potential role of modelling
Models  to assess the impact of dengue vaccine introduction,
based on current concepts of dengue transmission dynamics, may
be useful, particularly in the context of assessing potential herd
protection [49].
5.  Conclusions
Current candidate LATDVs in clinical trials appear to have
acceptable short-term safety proﬁles, however their long-term
safety has yet to be conﬁrmed. Severe disease due to vaccine failure
and vaccine-induced immune enhancement of disease are likely
to be indistinguishable in individual vaccinees and beneﬁt-risk
assessments will have to rely on epidemiological studies. Both
human host and viral factors could theoretically inﬂuence vaccine
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afety and merit careful evaluation in long-term safety assessments
f LATDVs. Randomized controlled study designs, such as in Phase
II studies, will provide the most powerful and unbiased datasets to
ssess these issues. The current WHO  guidance for follow-up of trial
articipants for 3–5 years post-vaccination should give a solid basis
or medium-term safety data, particularly if unvaccinated controls
an be maintained through this follow-up period. Further follow-up
f clinical trial subjects for longer periods is desirable to help estab-
ish the duration of protection and the risks of late adverse events.
n addition to follow-up in clinical trials, further long-term assess-
ent of LATDVs through special post-licensure studies is needed
o support beneﬁt-risk evaluations. Close collaboration between
icensing national regulatory authorities, and with respective vac-
ine sponsors, is recommended for a coordinated approach to the
esign and implementation of long-term follow-up studies.
In  this paper we have outlined methodological issues which sup-
ort a risk-based approach in the long-term assessment of LATDVs,
articularly beyond the follow-up of subjects in pre-licensure clini-
al trials. There are strong arguments for a coordinated approach to
evelop a comprehensive and robust post-licensure safety database
or dengue vaccines in parallel with their expanded use. Multi-
le stakeholders, including national public health, surveillance and
egulatory authorities; national ethical committees; dengue vac-
ine developers; academic and clinical experts in the diagnosis,
reatment and control of dengue; and international donors will
ll have roles in this coordinated approach. However, it should be
mphasized that not every country that deploys dengue vaccines
ill necessarily have to conduct studies of the kind outlined above.
ather, what is needed are exemplar studies, supported by system-
tic dengue surveillance, in carefully selected sites whose outcomes
ill inform national, regional and global vaccination strategies. As
or any other new vaccine, all countries should be aware of possi-
le vaccination risks. National regulatory authorities, particularly
n early introducer countries, may  consider to make licensing deci-
ions conditional on the conduct of speciﬁc post-licensure studies
o assess both effectiveness and safety.
Reliable and robust data on the long-term safety of LATDVs will
rimarily serve to establish a robust safety proﬁle given the theo-
etical risks. These data will also be critical to identify and manage
nsubstantiated safety concerns about severe dengue in vaccinees
hat could put vaccine programmes at risk.
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